Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Prospective Clinical Trials on Skin Wound Healing in Young and Aged Individuals (RESOLVE)

10. listopadu 2013 aktualizováno: David Lumenta, MD, Medical University of Vienna

Pilot Study of Prospective Clinical Trials on Skin Wound Healing in Young and Aged Individuals

Regular wound healing follows a well-ordered sequence of overlapping phases: inflammation, proliferation, maturation and remodelling.

In the young, damage to an organ mostly triggers fully regenerative mechanisms called "primary" wound healing. Repeated damage in young individuals may cause "secondary" wound healing eg. scar formation reflecting a rescue program, in which reorganisation has failed.

Organ failure in the ageing organism is characterized by a progressive loss of its capability to achieve an orderly reactivation of organ repair, and results in a combination of chronic inflammation and fibroproliferative, non-regenerative repair affecting several organs, including lung, liver and skin.

RESOLVE's objective is to identify, characterize, and validate molecular targets responsible for shifting primary organ repair towards fibroproliferative wound healing as a result of an age-dependent loss of regulatory control.

The structured approach is based on

  • different forms of wound healing,
  • different human diseases and
  • different genetic backgrounds,

aiming to provide future diagnostic tools in various organs, to create transgenic animal test systems, and to identify molecular targets involved in fibroproliferative wound healing.

Přehled studie

Detailní popis

Cutaneous scars are frequently encountered conditions. The process of wound repair, however, is complicated, and various factors contribute to different types of scarring (eg. hypertrophic, atrophic).

WP 2.1: Regular skin repair

In elective plastic surgery most excised operative skin specimens are usually discarded, and represent an excellent opportunity of harvesting skin biopsies without additional invasive measures. This work package analyzes skin samples of individuals after elective plastic surgery with normal wound healing serving as control group.

WP 2.2: Skin repair with and without hypertrophic scar formation

A classic example of fibroproliferative repair in the skin is hypertrophic scarring classified as a dermal skin lesion, which is raised above skin level, stays within the confines of the initial wound and increases in size by pushing out the margins of the scar without invading the surrounding normal tissue.

Hypertrophic scarring is a condition commonly observed after burns and in regions of prolonged wound healing (>21 days). The underlying pathology of hypertrophic scarring, however, is poorly understood. Hypertrophic scars can be managed conservatively, and only require surgical intervention under special circumstances.

This work package analyzes the clinical and molecular response to a standard treatment regimen in skin regions with and without hypertrophic scars after skin injuries.

WP 2.4: Wound healing in normal and diabetic individuals

Diabetes mellitus is a known factor to cause impaired wound healing. Due to microangiopathic, macroangiopathic and other conditions resulting from atherosclerosis and peripheral neuropathy wound healing in diabetic individuals is usually delayed (hypotrophic, atrophic) and often complicated by immunosuppression and superinfections. The rising prevalence of diabetes mellitus in the elderly population makes it necessary to understand its related processes in relevant clinical wound models.

Split-thickness skin-grafting is a commonly applied technique in plastic surgery, and donor sites of previously uninjured skin regions spontaneously heal within two weeks, representing an ideal condition to monitor clinical and molecular changes in diseased vs. non-diseased states.

This work package analyzes skin repair in donor sites of split-thickness skin grafts in non-diabetic and diabetic individuals.

Typ studie

Pozorovací

Zápis (Aktuální)

51

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Vienna, Rakousko, 1090
        • Division of Plastic and Reconstructive Surgery, Department of Surgery, Medical University of Vienna

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 85 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

WP 2.1 Individuals due for planned elective plastic surgery with regular wound healing

WP 2.2 Individuals, who suffered from burns, trauma or having undergone any type of previous surgery with and without hypertrophic scar formation

WP 2.4 Individuals, who require split-thickness skin grafting for skin defects with or without diabetes mellitus

Popis

WP2.1

Inclusion Criteria:

  • age 18-45 and 55-85 years, respectively

Exclusion Criteria:

  • past medical history of hypertrophic scarring or keloid disease
  • cardiac disease adversely affecting peripheral blood flow
  • active neoplastic disease
  • immunosuppressive condition, congenital or acquired
  • anemia
  • autoimmune disorder
  • acute or chronic renal failure
  • liver cirrhosis or active hepatitis
  • active substance-abuse disorder
  • severe underweight (body mass index <16)
  • endocrinological disorder
  • pregnancy or lactation for women of child-bearing age

WP2.2

Inclusion Criteria:

  • age 18-45 and 55-85 years, respectively
  • normal and/or hypertrophic scars
  • Baux score <100

Exclusion Criteria:

  • sepsis
  • electrical and/or chemical burn
  • clinically significant wound infection in areas of planned biopsies
  • cardiac disease adversely affecting peripheral blood flow
  • active neoplastic disease
  • immunosuppressive condition, congenital or acquired
  • autoimmune disorder
  • acute or chronic renal failure
  • liver cirrhosis or active hepatitis
  • active substance-abuse disorder
  • severe underweight (body mass index <16)
  • endocrinological disorder
  • pregnancy or lactation for women of child-bearing age

WP 2.4

Inclusion Criteria:

  • age 18-45 and 55-85 years, respectively

Exclusion Criteria:

  • cardiac disease adversely affecting peripheral blood flow
  • active neoplastic disease
  • immunosuppressive condition, congenital or acquired
  • anemia
  • autoimmune disorder
  • acute or chronic renal failure
  • liver cirrhosis or active hepatitis
  • substance-abuse disorder
  • severe underweight (body mass index <16)
  • thyroid function disorder
  • pregnancy or lactation for women of child-bearing age

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Časové perspektivy: Budoucí

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Regular wound healing, young
Regular skin repair, controlled wound healing conditions in young individuals
Taken from regularly discarded tissue during routine operation
Blood taking on day 0
Blood taking on day 90
Regular wound healing, aged
Regular skin repair, controlled wound healing conditions in aged individuals
Taken from regularly discarded tissue during routine operation
Blood taking on day 0
Blood taking on day 90
Hypertrophic scarring, young
Skin repair with and without hypertrophic scarring in young individuals
Blood taking on day 0
Blood taking on day 90
Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Hypertrophic scarring, aged
Skin repair with and without hypertrophic scarring in aged individuals
Blood taking on day 0
Blood taking on day 90
Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Non-diabetic, young
Skin repair in non-diabetic young individuals
Blood taking on day 0
Blood taking on day 90
Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Non-diabetic, aged
Skin repair in non-diabetic aged individuals
Blood taking on day 0
Blood taking on day 90
Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Diabetic, young
Skin repair in young diabetic individuals
Blood taking on day 0
Blood taking on day 90
Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Diabetic, aged
Skin repair in aged diabetic individuals
Blood taking on day 0
Blood taking on day 90
Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Časové okno
Time to wound healing / Scar maturation
Časové okno: day14, day90, day180
day14, day90, day180

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Lars P Kamolz, MD, MSc, MUW

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. července 2009

Primární dokončení (Aktuální)

1. července 2011

Termíny zápisu do studia

První předloženo

28. prosince 2009

První předloženo, které splnilo kritéria kontroly kvality

28. prosince 2009

První zveřejněno (Odhad)

29. prosince 2009

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Odhad)

13. listopadu 2013

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

10. listopadu 2013

Naposledy ověřeno

1. listopadu 2013

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • FP7-202047.WP.2.1-2.2-2.4
  • MUW-EK-Nr_015/2009 (Jiný identifikátor: MUVienna)

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Skin sample

Předplatit